Navigation Links
Pharmaxis' Aridol Authorised for Sale in Germany
Date:5/18/2008

SYDNEY, Australia, May 18 /Xinhua-PRnewswire-Firstcall/ -- Specialist Pharmaceutical Company Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) today announced that it has received national approval to market Aridol in Germany.

Aridol is indicated for measuring airway hyperresponsiveness and has been approved in 14 European countries under the mutual recognition procedure (MRP). The necessary national approvals that follow the MRP have now been received for Denmark, Germany, Ireland, The Netherlands, Portugal, Sweden, and the United Kingdom.

In Germany a total of 660,000 lung function tests are conducted annually, of which approximately 90% are conducted by office-based physicians and the remainder in the major hospitals. To enter the market, Pharmaxis will first negotiate with insurance companies that cover the office-based physician market before launching with a local distributor.

A simple-to-use airways inflammation test, Aridol is a dry powder administered to patients' lungs via a small hand-held inhaler. Doctors can use the results of this test to identify airway hyperresponsiveness -- a hallmark of asthma. Medications can be adjusted according to the severity of the disease. (see overleaf for more details on Aridol)

"We are pleased that Aridol is becoming globally recognised as a useful test for identifying airway hyperresponsiveness," said Pharmaxis CEO Dr Alan Robertson. "With this latest approval, Aridol is on the way to becoming the worldwide standard for detecting sensitive airways in people with conditions such as asthma.

"The Aridol test provides objective information on airway hyperresponsiveness and assists in the diagnosis and assessment of severity of asthma and how much medication should be used."

As well as being included as one of the tests recommended by the International Olympic Committee -- Medical Commission Independent Panel and the World Anti-Doping Agency, Aridol is also included in the GINA Report of
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. Pharmaxis Closes Share Purchase Plan
4. Pharmaxis Appoints Portuguese Distributor for Aridol
5. Pharmaxis Aridol Gains First Asian Approval
6. Pharmaxis Investor Conference Call
7. Pharmaxis to Apply to Market Bronchitol in Australia
8. Pharmaxis First Steps into China
9. Aridol(TM) Endorsed by International Olympic Committee
10. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
11. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in automated ... for hospitals, will be exhibiting at booth #209 at ... & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... hospitals cleaner, reducing infection risk and saving millions in ... Staff will be available at booth #209 to ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... TUSTIN, Calif., Sept. 1 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 ... New York Palace Hotel in New York City. , , ... the Investors section of Peregrine,s website at www.peregrineinc.com . ...
... COPENHAGEN and OSLO, September ... medicines company, today announced that it,has appointed two ... Robert Burns, previously CEO of Celldex Therapeutics Inc., ... new Chief Executive,Officer. Dr Alexander Duncan, previously SVP ...
... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that its Senior ... will present a corporate overview at the upcoming Rodman ... September 9, 2009 at 12:30 p.m. (eastern time) in ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
(Date:7/29/2014)... If you,ve ever ordered the wrong food at a restaurant, ... may have less to do with what you want and ... After analyzing 217 menus and the selections of over 300 ... International Journal of Hospitality Management showed that when it ... most: what you see on the menu and how you ...
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... have developed an easier method to create DNAprotein ... involved in diagnosing diseases. , DNA linked to ... partnership that can be used in diagnostic techniques, ... tag proteins with DNA can be used ... visualisation of biological material. The method also provides ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... in their response to sleep deprivation, but the biological ... Researchers have now found that a genetic difference in ... sensitive to the effects of sleep deprivation. The findings, ... the University of Surrey's Sleep Research Center, appear online ...
... upon a massive database established with funds from the ... of the National Institutes of Health (NIH), scientists have ... influenza A virus epitopes--the critical sites on the virus ... reported by researchers at the La Jolla Institute for ...
... first draft of the horse genome sequence has been ... use by biomedical and veterinary researchers around the globe, ... today. , The $15 million effort to sequence the ... of the horse (Equus caballus) was funded by the ...
Cached Biology News:Individual differences in a clock gene predict decline of performance during sleep deprivation 2New details on how the immune system recognizes influenza 2New details on how the immune system recognizes influenza 3New details on how the immune system recognizes influenza 4Horse genome assembled 2Horse genome assembled 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: